Prashant Reddy

Prashant Reddy

T. Prashant Reddy graduated from the National Law School of India University, Bangalore, with a B.A.LLB (Hons.) degree in 2008. He later graduated with a LLM degree (Law, Science & Technology) from the Stanford Law School in 2013. Prashant has worked with law firms in Delhi and in academia in India and Singapore. He is also co-author of the book Create, Copy, Disrupt: India's Intellectual Property Dilemmas (OUP).

SpicyIP Tidbit: World Health Statistics 2008


The World Health Organization has recently released the ‘World Health Statistics 2008’. To quote from the introduction of the Report World Health Statistics 2008 presents the most recent available health statistics for WHO’s 193 Member States. This fourth edition includes 10 highlights of health statistics as well as data on an expanded set of over 70 key health indicators. The indicators were selected on the basis of their relevance to global health monitoring and considerations of data availability, accuracy and…


Read More »
Uncategorized

The Access to Medicine Index released – Ranking Pharmaceutical Companies


Starting from the Pretoria patent litigation in South Africa to the Novartis patent litigation in Chennai last year the big pharmaceutical companies in the world have endured a particularly brutal image bashing exercise due to a series of strategic mistakes which have (rightly and wrongly) portrayed them as putting profits over patients. Obviously the negative publicity was beginning to worry institutional investors and when these concerns were coupled with philanthropic charities such as the Access to Medicine Foundation, the world…


Read More »

Patent Litigation in the Himachal Pradesh High Court


Shamnad recently forwarded me a judgment of the Himachal Pradesh High Court passed in a case regarding the validity of a patent. I’m pleased to inform our readers that, although this is probably one of the first such patent cases in the HPHC, the Division Bench consisting of Justice Gupta & Justice Ahuja have done quite a good job with the judgment. Although the judgment is not extensively researched it has no major conceptual errors, it is quite lucid, it…


Read More »
Uncategorized

SpicyIP Tidbit: WHO adopts resolution on public health, innovation & intellectual property


Readers may remember Sumathi’s extremely detailed post on the WHO’s Intergovernmental Working Group (IGWG) meet last month. As Sumathi put it “The fulcrum of the debate is nothing new: that the IP system, as it exists today, does not create economic incentives for private players to invest in research and development (R&D) for neglected diseases”. Last week the WHO finally came out with a resolution after two years of hard work by the IGWG. The substance of the resolution is…


Read More »
Drug Regulation

The DCGI is preparing a document to implement the patent-registration linkage system


Readers may remember that SpicyIP had recently carried an extensive post in regards the ‘Patent-Registration’ linkage system that was proposed by the DGCI. Pharmabiz.com reported a couple of days ago that the DCGI is preparing a document outlining a system to implement the linkage system. Once the document is ready the DCGI has promised to make it available to the industry for debate and discussion to ensure that everybody’s interests are protected. The pharmabiz.com report also informs us that the…


Read More »
Drug Regulation Patent

Why is the DCGI trying to implement a ‘patent-registeration’ linkage system in India?


The Drug Controller General of India – Dr. Surinder Singh – has made a public statement that he intends to link up regulatory approval for drugs to the patenting system i.e. he has gone on to record to state that the DCGI will not grant regulatory approval for generic drugs if in case the innovator drug still has a valid patent covering it. Such a move would severely delay the entry of generics into the market. (The Mint, the Business…


Read More »

SpicyIP Tidbit: The ‘Public Interest’ factor in Brazil’s patenting system


IMAK’s Tahir Amin has written an incisive piece on the hurdles being faced by Gilead in its quest to patent Tenofovir in Brazil and the possible spin-offs for Indian companies in the process. What caught our eye however was the ‘public interest’ factor which Mr. Amin mentioned in his post. According to Mr. Amin when a patent is being granted in Brazil, apart from the conventional patent office approval, the invention if it is a pharmaceutical product will also be…


Read More »

SpicyIP Tidbit: Minister to ensure that reduced excise duty to reflect in drug prices


The Minister of Chemicals and Fertilisers Ram Vilas Paswan, who heads the pharmaceutical advisory forum has instructed drug companies that they will have to reduce their prices by atleast 4.58% since the excise duty on drugs has been scaled back from 16% to 8%. He also promised to strengthen the infrastructure of the pricing watch-dog – the National Pharmaceutical Pricing Authority (NPPA) – by introducing a 24 hour helpline for customers who want to complain about drug companies over-charging on…


Read More »

SpicyIP Tidbit: Appeals Court rules on two issues in the Roche-Cipla litigation


The Mint and the ET report that a division bench of the Delhi High Court, hearing Roche’s appeal against the judgment of the single judge, have restained Cipla from exporting Erlocip to any country where Roche already has a patent for the drug. This is a mere restatement of the obvious and more over its a moot point as to whether the issue of export is even within the jurisdiction of the Delhi High Court. If Cipla does export to…


Read More »

Roche v. Cipla: The ‘Mint’ interviews Roche India’s MD on the recently concluded Tarceva litigation


The Mint recently carried an interview of Mr. Girish Telang, managing director of Roche Scientific India Pvt Ltd, the Indian unit of Switzerland-based F Hoffmann-La Roche Ltd. Incidentally this interview seems to be one of the few public statements by Roche, in regards, its high profile litigation against Cipla over Tarceva. (We’ve blogged about the Roche v. Cipla litigation here.) SpicyIP however was rather surprised by the re-statement of some facts by Mr. Telang, since all these facts were very…


Read More »